Ty Howton

Ty Howton has served as Sarepta Therapeutics’ executive vice president, general counsel, and corporate secretary since November 2012. Over the last several years, Sarepta has built an impressive and competitive position in Duchenne muscular dystrophy (DMD), and more recently in gene therapies for Limb-girdle muscular dystrophy (LGMD) diseases, MPS IIIA, and other central nervous system (CNS) disorders, totaling over 20 therapies in various stages of development. As part of his role at Sarepta, Ty leads legal, quality, and compliance functions to ensure excellence as Sarepta works to rapidly advance an industry-leading genetic medicine pipeline.

Prior to joining Sarepta, Mr. Howton served as senior vice president, chief legal officer, and a member of the executive team at Vertex Pharmaceuticals, a publicly traded biotechnology company. In this capacity, he participated in the general management of the company and oversaw all aspects of the Vertex global legal and compliance departments. Prior to his appointment as chief legal officer at Vertex, Mr. Howton served as chief compliance officer. In this capacity, he was responsible for designing and implementing the Vertex corporate compliance program as well as chairing the company’s corporate compliance committee. Prior to joining Vertex, Mr. Howton worked at Genentech, a biotechnology company, where he served in a number of legal roles before becoming the company’s chief health care compliance officer. Prior to joining Genentech, Mr. Howton was a member of the Sidley Austin corporate health care practice, where he advised on corporate transactions involving life science companies and provided regulatory counsel.

Mr. Howton holds a B.A. from Yale University and a J.D. from Northwestern University School of Law.